<DOC>
	<DOCNO>NCT00005011</DOCNO>
	<brief_summary>This study investigate effect symptom combine treatment estrogen progesterone woman severe premenstrual syndrome ( PMDD ) . Studies indicate woman PMS experience improvement symptom follow treatment leuprolide acetate , estrogen progesterone level low . Women PMS , woman without disorder , experience return symptom within approximately week re-exposure either estrogen progesterone . The cause hormone-induced depression remain unclear . It know whether depressed mood due simply change level estrogen progesterone whether would remit follow continued exposure stable level estrogen progesterone . This study determine whether maintenance stable hormone level prevent mood disturbance woman PMS . Participants study receive leuprolide acetate injection month 6 month . After 2 month , woman whose symptom improve receive skin patch contain either estrogen placebo ( inactive substance ) ask take daily suppository contain either progesterone placebo . Women whose symptom PMS respond leuprolide treatment 2 month end study offer treatment . Participants see nurse clinic every two week fill rating blood drawn measure hormone level .</brief_summary>
	<brief_title>Combined Hormone Replacement Menstrually-Related Mood Disorders</brief_title>
	<detailed_description>Results previous protocol ( # 90-M-0088 92-M-0174 ) demonstrate woman menstrually-related mood disorder ( MRMD ) , woman lack disorder , experience mood deterioration within approximately week exposure either estradiol progesterone context gonadal suppression ( induce use depot gonadotropin release hormone agonist , leuprolide acetate ) . It unknown whether hormone-induced depression occur consequent change gonadal steroid level simple exposure level critical threshold . Additionally , since symptom depression stimulate hormone addback appear remit fourth week hormone administration , unclear whether continued administration hormone would result continued repeat experience depression whether symptom would appear subsequent initial precipitate episode . To address point uncertainty , first establish efficacy gonadal suppression MRMD subject administer depot leuprolide acetate three month administer estradiol progesterone continuous fashion three month determine whether maintenance stable gonadal steroid level prevent characteristic cyclic mood disorder .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA : The subject study woman meet criterion MRMD describe Protocol # 81M0126 , The Phenomenology Biophysiology Menstruallyrelated Mood Behavioral Disorders . In brief , criterion include follow : 1 . History within last two year least six month menstruallyrelated mood behavioral disturbance least moderate severityi.e. , disturbance distinct appearance associate notable degree subjective distress interference life activity ; 2 . Symptoms sudden offset absence significant symptomatology follicular phase ; 3 . Age 1850 ; 4 . Regular menstrual cycle ( 2135 day length ) , pregnant , good medical health ; 5 . Not pregnant ; 6 . In good medical health ; 5 ) Medication free . All patient participate protocol already participate Protocol No . 81M0126 prospectively confirm predictable relationship mood disorder premenstrual phase menstrual cycle ; i.e. , 30 % change severity symptom self rating scale , relative range scale employ , seven day premenstrually compare seven day postmenstrually two three month study . This method form basis NIMH PMS Workgroup diagnostic guideline produce result highly convergent effect size method diagnose PMS . All subject require use nonhormonal form birth control ( e.g . barrier method exception IUD ) avoid pregnancy study . EXLUSION CRITERIA : The following condition , also , constitute contraindication treatment hormonal therapy preclude patient 's participate protocol : 1 . Current Axis I psychiatric diagnosis 2 . History endometriosis ; 3 . Diagnosis illdefined , obscure pelvic lesion , particularly undiagnosed ovarian enlargement ; 4 . Hepatic disease manifest abnormal liver function test ; 5 . History mammary carcinoma ; 6 . History pulmonary embolism phlebothrombosis ; 7 . Undiagnosed vaginal bleeding ; 8 . Porphyries ; 9 . Diabetes mellitus ; 10 . History malignant melanoma ; 11 . Cholecystitis pancreatitis ; 12 . Cardiovascular renal disease ; 13 . Pregnancy ; 14 . Significant clinical laboratory abnormality</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 28, 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Menstrual Cycle</keyword>
	<keyword>Gonadal Steroids</keyword>
	<keyword>GnRH Agonist</keyword>
	<keyword>PMS</keyword>
	<keyword>Estradiol</keyword>
	<keyword>Progesterone</keyword>
	<keyword>Mood</keyword>
	<keyword>MRMD</keyword>
	<keyword>PMDD</keyword>
	<keyword>Menstrually Related Mood Disorders</keyword>
</DOC>